Benzinga | May 17, 2021 04:26PM EDT

Pulmonx Corporation Highlights Presentation Of Long-Term Follow-Up Data From TRANSFORM Study At American Thoracic Society Virtual 2021 International Conference.

REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for severe lung disease, announced that key long-term follow-up data from the TRANSFORM(r) study was presented at the American Thoracic Society (ATS) virtual 2021 International Conference. The new data confirm the long-term benefits of the Zephyr(r) Endobronchial Valve (Zephyr Valve), the first minimally invasive procedure to treat patients with severe COPD/emphysema. The study shows that the Zephyr Valves provide significant benefits to patients including improvements over baseline in lung function and quality of life out to at least 24 months, and improvements in exercise capacity out to at least 18 months.i The Zephyr Valves are placed during a bronchoscopy procedure, so these benefits are achieved without the need for major surgery.